SIGA Technologies, Inc. (OTCMKTS:SIGA) Director Paul G. Savas purchased 10,000 shares of SIGA Technologies stock in a transaction on Monday, November 12th. The stock was purchased at an average price of $5.01 per share, for a total transaction of $50,100.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of SIGA stock opened at $5.36 on Wednesday. SIGA Technologies, Inc. has a 1 year low of $3.90 and a 1 year high of $8.47.

Hedge funds have recently made changes to their positions in the company. Acuitas Investments LLC lifted its position in shares of SIGA Technologies by 227.0% during the second quarter. Acuitas Investments LLC now owns 468,794 shares of the biotechnology company’s stock worth $2,785,000 after purchasing an additional 325,410 shares in the last quarter. Wells Fargo & Company MN acquired a new position in SIGA Technologies in the first quarter valued at approximately $104,000. Rhumbline Advisers acquired a new position in SIGA Technologies in the second quarter valued at approximately $282,000. Millennium Management LLC acquired a new position in SIGA Technologies in the first quarter valued at approximately $309,000. Finally, Renaissance Technologies LLC acquired a new position in SIGA Technologies in the second quarter valued at approximately $1,158,000. Institutional investors own 6.66% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “SIGA Technologies, Inc. (SIGA) Director Paul G. Savas Buys 10,000 Shares of Stock” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/11/14/siga-technologies-inc-siga-director-paul-g-savas-buys-10000-shares-of-stock.html.

SIGA Technologies Company Profile

SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.